With new Wegovy data in hand, Novo Nordisk will file for approval in MASH

Taking stock of the drug industry, from the lab to the medicine chest

November 1, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Scott Olson/Getty Images STAT+ | With new Wegovy data in hand, Novo Nordisk will file for approval in MASH After 72 weeks in a Phase 3 trial, 37% of patients on the drug experienced an improvement in liver scarring, with no worsening of their disease. By Elaine Chen STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman STAT+ | Opinion: Precision medicine can't fulfill its promise without better diagnostics If you think of precision medicine as a highly specialized instrument, it will only ever be as good as its calibration. By Amit Agrawal

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser